Subcutaneous Amivantamab for NSCLC Could Benefit Patients, Practices: Balazs Halmos, MD | AJMC
Subcutaneous Amivantamab for NSCLC Could Benefit Patients, Pr…
5 months ago
ajmc.com
Promising Efficacy Seen With Amivantamab Regimen in R/R Metastatic CRC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Promising Efficacy Seen With Amivantamab Regimen in R/R Met…
2 months ago
targetedonc.com
Dr Sabari on the FDA Approval of Subcutaneous Amivantamab for EGFR-Mutant NSCLC | OncLive
Dr Sabari on the FDA Approval of Subcutaneous Amivantamab for E…
3 months ago
onclive.com
FDA Approval of Subcutaneous Amivantamab Is Significant Step Forward in NSCLC: Martin Dietrich, MD, PhD | AJMC
FDA Approval of Subcutaneous Amivantamab Is Significant Step F…
3 months ago
ajmc.com
How Clinical Trial Data Have Shaped Amivantamab Use in Practice for EGFR-Mutated NSCLC | OncLive
How Clinical Trial Data Have Shaped Amivantamab Use in Practice for …
3 weeks ago
onclive.com
Treatment Options for EGFRm NSCLC: Amivantamab Lazertinib
Treatment Options for EGFRm NSCLC: Amivantamab Lazertinib
130 viewsFeb 21, 2025
vumedi.com
Dr Joshua Sabari Discusses Amivantamab’s First-Line Approval for NSCLC | AJMC
Dr Joshua Sabari Discusses Amivantamab’s First-Line Approv…
Mar 4, 2024
ajmc.com
3:48
Amivantamab Accolades Add Up for NSCLC | AJMC
Sep 27, 2024
ajmc.com
Mitigating Potential IRRs with Amivantamab: Clinical Insights fro…
9 months ago
onclive.com
Amivantamab Trial Promises New Hope for Colorectal Cancer Treat…
10 months ago
ajmc.com
8:58
Subcutaneous Amivantamab vs Intravenous Amivantamab, Both i…
Jun 25, 2024
onclive.com
Balancing Treatment Intensity and Resistance Mechanisms in First-Li…
Feb 27, 2025
targetedonc.com
2021 ASCO Review on EGFR Resistance Strategies in NSCLC: …
275 viewsNov 21, 2021
vumedi.com
Amivantamab Plus Lazertinib vs Osimertinib in First-Line EGFR-Mu…
Jun 19, 2024
onclive.com
13:44
Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Tre…
Nov 30, 2023
onclive.com
Dr Girard on the Efficacy of First-Line Amivantamab Plus Chemothe…
Oct 21, 2023
onclive.com
Johnson & Johnson Reports 45% Response Rate for Subcutaneous …
5 months ago
marketscreener.com
ASCO® 2024 Insights: "CHRYSALIS-2 Trial - Amivantamab Lazertinib i…
84 viewsJun 14, 2024
vumedi.com
3:22
Amivantamab in NSCLC: Interpreting MARIPOSA and Guide…
3 months ago
pharmacytimes.com
PAPILLON Study - Amivantamab Chemo vs. Chemo as 1L Treatmen…
854 viewsNov 17, 2023
vumedi.com
Novel Mechanisms Set FDA-Approved Amivantamab-Lazertini…
Aug 30, 2024
ajmc.com
3:38
Updates from PAPILLON: 1L Amivantamab Chemotherapy in A…
Nov 14, 2023
targetedonc.com
6:53
Amivantamab Lazertinib in EGFR-Mutated Advanced NSCLC: Result…
Nov 14, 2023
targetedonc.com
Adverse Event Management Strategies for Amivantamab-Base…
Feb 19, 2025
onclive.com
Amivantamab Toxicity Mitigation Strategies in the Treatment of EGF…
Apr 7, 2025
onclive.com
Insights from COCOON: Prophylactic Dermatologic Manag…
1 year ago
targetedonc.com
Dr Pietrantonio on Future Directions of Evaluating Amivantamab in CR…
Apr 4, 2025
onclive.com
1:34
Dr Sabari on the FDA Approval of Amivantamab/Lazertinib in EGFR …
Sep 4, 2024
onclive.com
Dr Leighl on Amivantamab in Advanced NSCLC With MET Exon …
Sep 12, 2023
onclive.com
1:14
Predictive Biomarkers for Treatment With Amivantamab Plus Lazertini…
Apr 29, 2024
onclive.com
See more videos
Static thumbnail place holder